Image may be NSFW.
Clik here to view.
Novartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease.
The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide. Seebri Breezhaler is a fixed-dose formulation of glycopyrronium bromide.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis launches COPD inhalers in China appeared first on MassDevice.
